

# OmiCrohn


## A study on choosing treatment based on a blood test versus standard care in adults with Crohn's disease

### Background

There are many medications available for people with Crohn's disease. Unfortunately, it is difficult for doctors to know in advance which medication will work best for a particular patient. As a result, medication may need to be switched, which is unpleasant and can affect the course of the disease.

We have developed a blood test that is likely to help predict which medication (vedolizumab or ustekinumab) will work well.

The aim of this study is to investigate whether this blood test is better at selecting the right medication than doctors.



### Eligible patients

- Have active Crohn's disease
- Are eligible for vedolizumab or ustekinumab
- Have received no more than one biological medication in the past

### Study Objectives

- Less inflammation visible during endoscopy
- Fewer symptoms (measured via questionnaires)

### Expected Outcomes

- Fewer symptoms and less inflammation in patients for whom the blood test selected the medication
- More patients achieving complete remission when the blood test selected the medication

### Expected Benefits for Patients

If the blood test can select the most suitable medication for patients, this offers many advantages:

- Faster symptom relief
- Fewer hospitalizations and surgeries
- More personalized treatment
- Improved quality of life